<DOC>
	<DOC>NCT00093015</DOC>
	<brief_summary>The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 g/dL on (1) all-cause mortality and nonfatal cardiovascular events, and (2) progression to end-stage renal disease or death, in subjects with chronic kidney disease and type 2 diabetes mellitus. Academic PI/Executive Committee Chairman: Marc Pfeffer, MD, PhD</brief_summary>
	<brief_title>Trial to Reduce Cardiovascular Events With AranespÂ® Therapy (TREAT)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Hemoglobin less than or equal to 11 g/dL History of Chronic Kidney Disease eGFR (estimated glomerular filtration rate) greater than or equal to 20 mL/min/1.73 m2 and less than or equal to 60 mL/min/1.73 m2 Tsat (transferrin saturation) greater than 15% Uncontrolled hypertension Erythropoietic protein use within 12 weeks of randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>